Familial Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH)
Conditions
Keywords
cholesterol, newborn screening, pediatric, infant
Brief summary
The goal of this clinical trial is to identify different types of Familial Hypercholesterolemia (FH) in infants and newborns. Participants will: * undergo a cheek swab for genetic testing (parents only) * have 5 blood samples collected Participants can expect to be in the trial for 2 years.
Detailed description
ORIGIN-FH is a two-phase cohort study that will identify and enroll expectant parents where one or both partners has phenotypic and/or genotypic familial hypercholesterolemia in order to prospectively screen and diagnose their newborns with HoFH, HeFH, or are unaffected by FH.
Interventions
DIAGNOSTIC_TESTScreening for FH
Participants will provide 5 blood samples for screening for FH.
Sponsors
University of Wisconsin, Madison
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
- parent participant: * Individuals in the expectant partnership providing informed consent are at least 18 years of age. * Ability to understand and willingness to sign a written informed consent document. * Willingness to comply with all study procedures and be available for the duration of the study. * Expectant parent (currently pregnant with fetus ≥12 weeks gestation) where one or both partners have been diagnosed with possible or definite HoFH or HeFH based on Dutch Lipid Clinic Network (DLCN) or confirmed diagnosis from a healthcare provider. At minimum, at least one parent with HoFH or HeFH must be willing to consent to study participation. However, both parents will be invited to participate. * Parent(s) commit to using local laboratory services for infant blood samples, with mobile phlebotomy used as an alternative if available in their area. Inclusion Criteria - newborn participant: * Newborn does not have any congenital abnormalities or medical conditions that may interfere with collection of dried blood spot (DBS) specimen and newborn does not require admission to neonatal intensive care unit.
Exclusion criteria
- parent and newborn participants: * Expectant partnership where neither partner meets diagnostic criteria for HeFH or HoFH. * Parent refuses consent for newborn's study participation. * Newborn has medical condition precluding DBS specimen collection, or a newborn's DBS specimen is not collected by 1 week of age. * Not suitable for study participation due to other reasons at the discretion of the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of diagnostically confirmed HoFH newborns born to expectant parent partnerships where one or both partners have phenotypic HoFH or HeFH. | 2 years |
| Number of diagnostically confirmed HeFH newborns born to expectant parent partnerships where one or both partners have phenotypic HoFH or HeFH. | 2 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Differences in Low Density Lipoprotein Cholesterol (LDL-C) | 1 month, 2 years | LDL-C will be measured and compared between newborns with HeFH/HoFH and those not affected by FH. |
| Differences in Total Cholesterol (TC) | 1 month, 2 years | TC will be measured and compared between newborns with HeFH/HoFH and those not affected by FH. |
| Differences in Apolipoprotein B (apoB) | 1 month, 2 years | ApoB will be measured and compared between newborns with HeFH/HoFH and those not affected by FH. |
| Differences in Lipoprotein A (Lp(a)) | 1 month, 2 years | Lp(a) will be measured and compared between newborns with HeFH/HoFH and those not affected by FH. |
Countries
United States
Contacts
CONTACTXiao Zhang, PhD
PRINCIPAL_INVESTIGATORAmy Peterson, MD, MS
University of Wisconsin, Madison
Outcome results
None listed